Evidence map›Paper›PMID 33221238›Full record

ArticleJACC. Cardiovascular imaging2021

Label-Free Visualization and Quantification of Biochemical Markers of Atherosclerotic Plaque Progression Using Intravascular Fluorescence Lifetime.

Julien Bec, Deborah Vela, Jennifer E Phipps, Michael Agung, Jakob Unger, Kenneth B Margulies, Jeffrey A Southard, L Maximilian Buja, Laura Marcu

Open access · hybridAbstract read
In one paragraph

Article in JACC. Cardiovascular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Julien BecDepartment of Biomedical Engineering, University of California, Davis, California, USA.
Deborah VelaDepartment of Cardiovascular Pathology Research, Texas Heart Institute, Houston, Texas, USA.
Jennifer E PhippsDepartment of Biomedical Engineering, University of California, Davis, California, USA.
Michael AgungDepartment of Biomedical Engineering, University of California, Davis, California, USA.
Jakob UngerDepartment of Biomedical Engineering, University of California, Davis, California, USA.
Kenneth B MarguliesCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jeffrey A SouthardDivision of Cardiovascular Medicine, UC Davis Health System, University of California-Davis, Sacramento, California, USA.
L Maximilian BujaDepartment of Cardiovascular Pathology Research, Texas Heart Institute, Houston, Texas, USA; Department of Pathology and Laboratory Medicine, the University of Texas Health Science Center at Houston, Houston, Texas, USA.
Laura MarcuDepartment of Biomedical Engineering, University of California, Davis, California, USA. Electronic address: lmarcu@ucdavis.edu.
University of California, Davis · USCardiovascular Institute of the South · USThe University of Texas Health Science Center at Houston · US

Funding

Integrative genomics of human heart failureR01HL105993 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ASHLEY, EUAN A, CAPPOLA, THOMAS P. · 2011 to 2014
$8.9M
Time-Resolved Spectroscopy of Unstable Arterial PlaquesR01HL067377 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MARCU, LAURA · 2001 to 2015
$5.2M
NHLBI NIH HHS R01 HL067377NHLBI NIH HHS R01 HL105993
6 · The paper itself

Abstract

objectivesThis study aimed to systematically investigate whether plaque autofluorescence properties assessed with intravascular fluorescence lifetime imaging (FLIm) can provide qualitative and quantitative information about intimal composition and improve the characterization of atherosclerosis lesions.

backgroundDespite advances in cardiovascular diagnostics, the analytic tools and imaging technologies currently available have limited capabilities for evaluating in situ biochemical changes associated with luminal surface features. Earlier studies of small number of samples have shown differences among the autofluorescence lifetime signature of well-defined lesions, but a systematic pixel-level evaluation of fluorescence signatures associated with various histological features is lacking and needed to better understand the origins of fluorescence contrast.

methodsHuman coronary artery segments (n = 32) were analyzed with a bimodal catheter system combining multispectral FLIm with intravascular ultrasonography compatible with in vivo coronary imaging. Various histological components present along the luminal surface (200-μm depth) were systematically tabulated (12 sectors) from each serial histological section (n = 204). Morphological information provided by ultrasonography allowed for the accurate registration of imaging data with histology data. The relationships between histological findings and FLIm parameters obtained from 3 spectral channels at each measurement location (n = 33,980) were characterized.

resultsOur findings indicate that fluorescence lifetime from different spectral bands can be used to quantitatively predict the superficial presence of macrophage foam cells (mFCs) (area under the receiver-operator characteristic curve: 0.94) and extracellular lipid content in advanced lesions (lifetime increase in 540-nm band), detect superficial calcium (lifetime decrease in 450-nm band area under the receiver-operator characteristic curve: 0.90), and possibly detect lesions consistent with active plaque formation such as pathological intimal thickening and healed thrombus regions (lifetime increase in 390-nm band).

conclusionsOur findings indicate that autofluorescence lifetime provides valuable information for characterizing atherosclerotic lesions in coronary arteries. Specifically, FLIm can be used to identify key phenomena linked with plaque progression (e.g., peroxidized-lipid-rich mFC accumulation and recent plaque formation).

Indexed as

Coronary Artery DiseasePlaque, AtheroscleroticBiomarkersCoronary VesselsHumansOptical ImagingPredictive Value of TestsUltrasonography, InterventionalBiomarkersatherosclerosiscoronary artery diseaseimaginginflammationlipids and cholesterolpercutaneous coronary interventionultrasonographyultrasound

Identifiers

PMID33221238
PMCPMC8116358
OpenAlexW3101333118

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.